ArticleNPJ precision oncology2018
Superhydrophobic lab-on-chip measures secretome protonation state and provides a personalized risk assessment of sporadic tumour.
Article in NPJ precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Clinical Translatable and Transparency of Neural Network for Blood-Based Personalized Cancer Risk.Mayo Clinic proceedings. Digital health · 2026Article
- Circulating tumor cells and clusters as liquid biomarkers for the diagnosis and prognosis of neuroblastoma.BMC cancer · 2025Article
- Artificial intelligence for cancer screening and surveillance.ESMO real world data and digital oncology · 2024Review
- Long-Term Stability in Electronic Properties of Textile Organic Electrochemical Transistors for Integrated Applications.Materials (Basel, Switzerland) · 2023Article
- Minimal residual disease assessment of papillary thyroid carcinoma through circulating tumor cell-based cytology.Cancer medicine · 2022Article
- Liquid Biopsy-Guided Interventional Oncology: A Proof of Concept with a Special Focus on Radiotherapy and Radiology.Cancers · 2022Review
- Micro/Nanopatterned Superhydrophobic Surfaces Fabrication for Biomolecules and Biomaterials Manipulation and Analysis.Micromachines · 2021Review
- Methylglyoxal Adducts Levels in Blood Measured onNanomaterials (Basel, Switzerland) · 2021Article
- Liquid Biopsy for Cancer Cachexia: Focus on Muscle-Derived microRNAs.International journal of molecular sciences · 2021Review
- Review
- Nanoparticles: A New Approach to Upgrade Cancer Diagnosis and Treatment.Nanoscale research letters · 2021Review
- Pilocytic Astrocytoma-Derived Cells in Peripheral Blood: A Case Report.Frontiers in oncology · 2021Article
- HIF-1, the Warburg Effect, and Macrophage/Microglia Polarization Potential Role in COVID-19 Pathogenesis.Oxidative medicine and cellular longevity · 2021Review
- Microenvironment Molecular Profile Combining Glycation Adducts and Cytokines Patterns on Secretome of Short-term Blood-derived Cultures during Tumour Progression.International journal of molecular sciences · 2020Article
- Tailoring Chemometric Models on Blood-Derived Cultures Secretome to Assess Personalized Cancer Risk Score.Cancers · 2020Article
- Emerging Designs of Electronic Devices in Biomedicine.Micromachines · 2020Review
- The paradigm of stem cell secretome in tissue repair and regeneration: Present and future perspectives.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secretome of primary cultures is an accessible source of biological markers compared to more complex and less decipherable mixtures such as serum or plasma. The protonation state (PS) of secretome reflects the metabolism of cells and can be used for cancer early detection. Here, we demonstrate a superhydrophobic organic electrochemical device that measures PS in a drop of secretome derived from liquid biopsies. Using data from the sensor and principal component analysis (PCA), we developed algorithms able to efficiently discriminate tumour patients from non-tumour patients. We then validated the results using mass spectrometry and biochemical analysis of samples. For the 36 patients across three independent cohorts, the method identified tumour patients with high sensitivity and identification as high as 100% (no false positives) with declared subjects at-risk, for sporadic cancer onset, by intermediate values of PS. This assay could impact on cancer risk management, individual's diagnosis and/or help clarify risk in healthy populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.